Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 12:18 pm Purchase |
2024-12-31 | 13G | Mural Oncology plc MURA |
ACORN BIOVENTURES, L.P. | 1,286,079 7.600% |
208,857 (+19.39%) |
Filing History |
| 2025-02-14 12:14 pm Purchase |
2024-12-31 | 13G | Puma Biotechnology, Inc. PBYI |
ACORN BIOVENTURES, L.P. | 3,940,052 8.000% |
660,612 (+20.14%) |
Filing History |
| 2024-11-14 12:12 pm Purchase |
2024-09-30 | 13G | Puma Biotechnology, Inc. PBYI |
ACORN BIOVENTURES, L.P. | 3,279,440 6.700% |
344,944 (+11.75%) |
Filing History |
| 2024-11-14 12:00 pm Purchase |
2024-08-09 | 13G | Mural Oncology plc MURA |
ACORN BIOVENTURES, L.P. | 1,077,222 6.300% |
228,700 (+26.95%) |
Filing History |
| 2024-10-09 4:01 pm Purchase |
2024-10-04 | 13G | OnKure Therapeutics, Inc. OKUR |
ACORN BIOVENTURES, L.P. | 1,439,674 11.400% |
1,439,674 (New Position) |
Filing History |
| 2024-08-13 4:43 pm Purchase |
2024-08-09 | 13G | Mural Oncology plc MURA |
ACORN BIOVENTURES, L.P. | 848,522 5.000% |
848,522 (New Position) |
Filing History |
| 2024-04-04 8:33 pm Purchase |
2024-03-25 | 13D | Q32 Bio Inc. QTTB |
ACORN BIOVENTURES, L.P. | 803,425 6.700% |
803,425 (New Position) |
Filing History |
| 2024-02-14 4:44 pm Purchase |
2022-06-30 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ACORN BIOVENTURES, L.P. | 17,755,869 9.990% |
17,755,869 (New Position) |
Filing History |
| 2024-02-13 5:16 pm Purchase |
2023-12-31 | 13G | OptiNose, Inc. OPTN |
ACORN BIOVENTURES, L.P. | 802,801 9.900% |
44,870 (+5.92%) |
Filing History |
| 2024-02-07 5:03 pm Sale |
2023-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC |
ACORN BIOVENTURES, L.P. | 0 0.000% |
-187,676 (Position Closed) |
Filing History |
| 2024-02-06 4:01 pm Sale |
2023-12-31 | 13G | Cardiff Oncology, Inc. CRDF |
ACORN BIOVENTURES, L.P. | 1,946,762 4.200% |
-1,096,411 (-36.03%) |
Filing History |
| 2024-02-06 3:59 pm Purchase |
2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
ACORN BIOVENTURES, L.P. | 2,761,825 6.300% |
2,761,825 (New Position) |
Filing History |
| 2024-02-06 3:57 pm Purchase |
2023-12-31 | 13G | BioAtla, Inc. BCAB |
ACORN BIOVENTURES, L.P. | 4,032,046 8.400% |
1,305,591 (+47.89%) |
Filing History |
| 2024-02-06 3:54 pm Purchase |
2023-12-31 | 13G | Puma Biotechnology, Inc. PBYI |
ACORN BIOVENTURES, L.P. | 2,934,496 6.200% |
194,561 (+7.10%) |
Filing History |
| 2023-09-01 10:18 am Purchase |
2023-08-22 | 13G | Puma Biotechnology, Inc. PBYI |
ACORN BIOVENTURES, L.P. | 2,739,935 5.800% |
2,739,935 (New Position) |
Filing History |
| 2023-04-27 12:11 pm Purchase |
2023-04-20 | 13G | BioAtla, Inc. BCAB |
ACORN BIOVENTURES, L.P. | 2,726,455 5.700% |
2,726,455 (New Position) |
Filing History |
| 2023-04-03 1:46 pm Purchase |
2023-03-15 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
ACORN BIOVENTURES, L.P. | 2,326,528 5.300% |
2,326,528 (New Position) |
Filing History |
| 2023-01-26 1:36 pm Purchase |
2022-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC |
ACORN BIOVENTURES, L.P. | 187,676 9.990% |
31,377 (+20.07%) |
Filing History |
| 2023-01-26 1:30 pm Unchanged |
2023-01-26 | 13G | Cardiff Oncology, Inc. CRDF |
ACORN BIOVENTURES, L.P. | 3,043,173 6.380% |
0 (Unchanged) |
Filing History |
| 2023-01-26 1:28 pm Sale |
2022-09-13 | 13D | Cardiff Oncology, Inc. CRDF |
ACORN BIOVENTURES, L.P. | 3,043,173 6.380% |
-2,947,666 (-49.20%) |
Filing History |